Adherence to antihypertensive agents improves risk reduction of end-stage renal disease

Kidney International

Volumn 84, Issue 3, 2013, Pages 570-577

  Roy, Louise ^a   White Guay, Brian ^a   Dorais, Marc ^a   Dragomir, Alice ^b   Lessard, Myriam ^a   Perreault, Sylvie ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

adherence to treatment; antihypertensive drugs; chronic renal insufficiency

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DATA BASE; DIABETES MELLITUS; DISEASE COURSE; DRUG USE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENDER; GOUT; HAZARD RATIO; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; STUDY DESIGN;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CANADA; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 84883465807     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.103     Document Type: Article

References (51)

1. Sarafidis PA, Li S, Chen SC et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008; 121: 332-340.
2. Zanchetti A. Impact of hypertension and antihypertensive treatment on organ damage. Am J Cardiol 1999; 84: 18K-24K.
3. Wright JT Jr, Douglas JG, Rahman M. Prevention of cardiovascular disease in hypertensive patients with normal renal function. Am J Kidney Dis 1998; 32(5 Suppl 3): S66-S79.
4. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18.
5. Tozawa M, Iseki K, Iseki C et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003; 41: 1341-1345.
6. Hsu CY, McCulloch CE, Darbinian J et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005; 165: 923-928.
7. Palmer AJ, Valentine WJ, Chen R et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 2008; 23: 1216-1223.
8. Palmer BF. Management of hypertension in patients with chronic kidney disease and diabetes mellitus. Am J Med 2008; 121(8 Suppl): S16-S22.
9. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
10. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
11. Chobanian AV. Shattuck Lecture. The hypertension paradox-more uncontrolled disease despite improved therapy. N Engl J Med 2009; 361: 878-887.
12. Wilkins K, Campbell NR, Joffres MR et al. Blood pressure in Canadian adults. Health Rep 2010; 21: 37-46.
13. Park J, Campese V. Clinical characteristics of resistant hypertension: The importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens (Greenwich) 2007; 9(1 Suppl 1): 7-12.
14. Chobanian AV. Shattuck Lecture. The hypertension paradox-more uncontrolled disease despite improved therapy. N Engl J Med 2009; 361: 878-887.
15. Jackson KC 2nd, Sheng X, Nelson RE et al. Adherence with multiplecombination antihypertensive pharmacotherapies in a US managed care database. Clin Ther 2008; 30: 1558-1563.
16. Caro JJ, Salas M, Speckman JL et al. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160: 31-37.
17. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006; 19: 1190-1196.
18. Kettani FZ, Dragomir A, Cote R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213-220.
19. Nelson MR, Reid CM, Ryan P et al. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006; 185: 487-489.
20. Perreault S, Dragomir A, Roy L et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010; 69: 74-84.
21. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-298.
22. Avram Z, Krishnan E. Hyperuricaemia-where nephrology meets rheumatology. Rheumatology (Oxford) 2008; 47: 960-964.
23. Cass A, Cunningham J, Wang Z et al. Social disadvantage and variation in the incidence of end-stage renal disease in Australian capital cities. Aust N Z J Public Health 2001; 25: 322-326.
24. Mangione F, Dal Canton A. The epidemic of chronic kidney disease: Looking at ageing and cardiovascular disease through kidney-shaped lenses. J Intern Med 2010; 268: 449-455.
25. Naicker S, Fabian J. Risk factors for the development of chronic kidney disease with HIV/AIDS. Clin Nephrol 2010; 74(Suppl 1): S51-S56.
26. Najafi I, Attari F, Islami F et al. Renal function and risk factors of moderate to severe chronic kidney disease in Golestan Province, northeast of Iran. PLoS One 2010; 5: E14216.
27. Palmer Alves T, Lewis J. Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: A social and economic dilemma. Clin Nephrol 2010; 74(Suppl 1): S72-S77.
28. Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007; 82: 1381-1390.
29. Atthobari J, Brantsma AH, Gansevoort RT et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: Results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006; 21: 3106-3114.
30. Bianchi S, Bigazzi R, Caiazza A et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-570.
31. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109(23 Suppl 1): III39-III43.
32. Lewis JB. Blood pressure control in chronic kidney disease: Is less really more? J Am Soc Nephrol 2010; 21: 1086-1092.
33. Sarnak MJ, Greene T, Wang X et al. The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342-351.
34. Appel LJ, Wright JT Jr, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929.
35. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
36. Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
37. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291-303.
38. Daskalopoulou SS, Delaney JA, Filion KB et al. Discontinuation of statin therapy following an acute myocardial infarction: A population-based study. Eur Heart J 2008; 29: 2083-2091.
39. Rifkin DE, Laws MB, Rao M et al. Medication adherence behavior and priorities among older adults with CKD: A semistructured interview study. Am J Kidney Dis 2010; 56: 439-446.
40. Choo PW, Rand CS, Inui TS et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 846-857.
41. Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e edn McGraw-Hill 2011.
42. Pan American Health Organization. Implementation of the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Epidemiol Bull 1997; 18: 1-4.
43. Hughes C. ICD-9 update 2011: Approaching the change to ICD-10 Fam Pract Manag 2010; 17: 15-16.
44. Tamblyn R, Lavoie G, Petrella L et al. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999-1009.
45. Monfared A, Rahme E, LeLorier J. Accuracy of ICD-9 diagnosis code '410' to identify episodes of hospitalizations for acute myocardial infarction in RAMQ. First Canadian Therapeutics Congress: Halifax, 2004.
46. Tamblyn R, Reid T, Mayo N et al. Using medical services claims to assess injuries in the elderly: Sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000; 53: 183-194.
47. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004; 57: 131-141.
48. The ALLHAT Officer and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967-1975.
49. Khan NA, McAlister FA, Rabkin SW et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2006; 22: 583-593.
50. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
51. Lee ET. Statistical Methods for Survival Data Analysis. John Wiley & Sons, 1992.